BioPharmX Corp (BPMX) Gets a Buy Rating from Maxim Group
In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on BioPharmX Corp (BPMX), with a price target of $1. The company’s shares closed yesterday at $0.16.
Vendetti observed: “Yesterday, after the Market close, BPMX reported a F3Q19 (Sep) GAAP loss per share inline with both our estimate and consensus.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 6.4% and a 48.9% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
The the analyst consensus on BioPharmX Corp is currently a Hold rating.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.